Biotech Values

[iwfal]

My guess is that IFN-L gets to market within 18 months of the first triple oral therapy becoming the norm. And if IFN is still necessary they take the market very very quickly

.

My predict from 1.5 years ago looks to have been substantially too conservative. At this point it looks like IFN-L gets to market well BEFORE the widespread use of any triple DAA therapy. Excluding the BMY 2DAAs, perhaps it even gets to market before any 2DAAs are approved for use with SOC.

(the wildcard of course is what happens if some other DAA shoots for approval as a standalone+SOC and then can get tested in after-approval trials (with, say, Telaprevir) which might go quicker because of the lack of corporate walls)